sanofi-aventis home

Print

|

E-mail a Colleague

|

Site Map

U.S. Residents Only

Important Safety Info.

|

Prescribing Info.

|

Ordering & Reimbursement

|

Patient Web Site

About Osteoarthritis of the Knee

HYALGAN® Facts

When to Use HYALGAN®

How to Use HYALGAN®

HYALGAN® - Proven Efficacy

Clinical Trial Library

Patient Support

It looks like you do not have an updated Flash Plug-in. To view the current page, please download it.

For osteoarthritis (OA) knee pain

HYALGAN® goes further

Long-lasting pain relief
Well-established safety
Helps relieve knee pain so you can keep on moving

Learn more http://www.hyalgan.com/hcp/facts/default.aspx

Ordering & Reimbursement

Make sure you have enough HYALGAN® on hand.
View the latest reimbursement information.

Read more tips http://www.hyalgan.com/hcp/resources/default.aspx

Injection Tutorial

For physicians new to HYALGAN® and those who wish to refine their technique.

Tutorial http://www.hyalgan.com/hcp/how/injection.aspx

Patient Profiles

See what HYALGAN® benefits mean to patients just like yours.

Learn more http://www.hyalgan.com/hcp/when/studies.aspx

Get HYALGAN® Updates

Register for e-mail updates about HYALGAN® and special offers.

Learn more http://www.hyalgan.com/hcp/resources/registration.aspx

Welcome to HYALGAN.com for Healthcare Professionals

For osteoarthritis (OA) knee pain

HYALGAN® goes further

Long-lasting pain relief⁸
Well-established safety¹⁰
Helps patients keep on moving⁸

The first FDA-approved hyaluronate therapy to treat osteoarthritis knee pain in the U.S.³²

Over 83 published clinical studies more than 25 million injections given worldwide.¹⁷^,¹⁸

Visit our InfoSite on MedScape for more information and to watch a free injection technique video. Medscape is a free registration site.

Important Safety Information for HYALGAN®

HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
The effectiveness of a single treatment cycle of less than 3 injections has not been established
In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.